- Home
- ACHV vs CTMX Comparison
ACHV vs CTMX Comparison
Compare ACHV & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- CTMX
- Stock Information
- Founded
- ACHV N/A
- CTMX 2008
- Country
- ACHV Canada
- CTMX United States
- Employees
- ACHV N/A
- CTMX N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- ACHV Health Care
- CTMX Health Care
- Exchange
- ACHV Nasdaq
- CTMX Nasdaq
- Market Cap
- ACHV 72.5M
- CTMX 60.7M
- IPO Year
- ACHV N/A
- CTMX 2015
- Fundamental
- Price
- ACHV $2.35
- CTMX $0.93
- Analyst Decision
- ACHV Strong Buy
- CTMX Buy
- Analyst Count
- ACHV 3
- CTMX 5
- Target Price
- ACHV $14.33
- CTMX $5.52
- AVG Volume (30 Days)
- ACHV 178.2K
- CTMX 2.4M
- Earning Date
- ACHV 05-13-2025
- CTMX 05-12-2025
- Dividend Yield
- ACHV N/A
- CTMX N/A
- EPS Growth
- ACHV N/A
- CTMX N/A
- EPS
- ACHV N/A
- CTMX 0.38
- Revenue
- ACHV N/A
- CTMX $138,103,000.00
- Revenue This Year
- ACHV N/A
- CTMX N/A
- Revenue Next Year
- ACHV N/A
- CTMX N/A
- P/E Ratio
- ACHV N/A
- CTMX $2.46
- Revenue Growth
- ACHV N/A
- CTMX 36.45
- 52 Week Low
- ACHV $1.84
- CTMX $0.40
- 52 Week High
- ACHV $5.59
- CTMX $2.81
- Technical
- Relative Strength Index (RSI)
- ACHV 46.09
- CTMX 61.33
- Support Level
- ACHV $2.32
- CTMX $0.63
- Resistance Level
- ACHV $2.69
- CTMX $1.04
- Average True Range (ATR)
- ACHV 0.18
- CTMX 0.11
- MACD
- ACHV 0.02
- CTMX 0.03
- Stochastic Oscillator
- ACHV 17.07
- CTMX 44.95
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.